期刊档案 · IMMUNOLOGY

Antibodies

ISSN 2073-4468 · MDPI AG · Switzerland

Antibodies 中科院 医学 4区(2025 年升级版),影响因子 3.3(官网公布),完全开放获取,收取 APC,金额未公布,近 24 个月 111 篇文章投稿到接收中位 44 天,2025 年发文 109 篇,ESCI、Scopus 收录。

影响因子3.3期刊官网公布的最新值
中科院分区医学 4区2025 年升级版大类 · 2026 新锐版 医学 3区
审稿周期44 天投稿到接收中位数 · 近 24 个月 111 篇文章 · PubMed
版面费收取 APC,金额未公布完全开放获取
录用比例—暂无反馈
年发文量109 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

Antibodies 由 MDPI AG 出版,属中科院医学大类(2025 升级版4区)。按 OpenAlex 近年发文统计,该刊主要发表 Monoclonal and Polyclonal Antibodies Research、Glycosylation and Glycoproteins Research、Protein purification and stability 等主题的论文,这 3 个主题约占 46.4%,主导子领域为 Molecular Biology、Immunology。(根据 OpenAlex 主题统计与中科院分区数据生成)

This journal covers all topics related to antibodies and antigens. Major topics of interest include (but are not limited to): Antibodies and the humoral immune response Antibody-producing cells (including B cells); Natural antibodies; Tumor antigens; Autoantigens; Fc receptors; Immunoregulatory molecules; Discovery, generation and selection of antibodies Monoclonal antibodies; Single-cell cloning of V-genes; Antibody selection (phage display, cell surface display and ribosome display); In vitro affinity maturation; Computational antibody design. Antibody structure and function Antibody–antigen interactions; Structural analysis of antibodies (X-ray and Cryo-TEM); Antibody sequence analysis and databases; Computational antibody modelling. Antibody engineering, conjugates and fusion proteins Antibody humanization; Antibody manufacturing; Antibody purification; Biophysical properties and characterization; Single-domain antibodies; Alternative binding proteins based on non-Ig scaffolds; Bispecific antibodies; Antibody fusion proteins; Antibody–drug conjugates. Antibodies in biomedical research and therapy Targets for antibody therapy; Antibodies for cancer therapy; Antibodies to treat autoimmune disorders; Other antibody therapies; Immunoassays; Antibodies for in vivo diagnostics; Bioanalytical assays and research tools.

摘自期刊官网 Aims & Scope

研究方向(LetPub):IMMUNOLOGY

主编 Arne Skerra出版商官网

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. Monoclonal and Polyclonal Antibodies ResearchMedicine30.2%
  2. Glycosylation and Glycoproteins ResearchBiochemistry, Genetics and Molecular Biology8.3%
  3. Protein purification and stabilityBiochemistry, Genetics and Molecular Biology8%
  4. CAR-T cell therapy researchMedicine5.3%
  5. T-cell and B-cell ImmunologyImmunology and Microbiology4.8%
  6. SARS-CoV-2 and COVID-19 ResearchMedicine4%
  7. HER2/EGFR in Cancer ResearchMedicine3.8%
  8. Immunotherapy and Immune ResponsesImmunology and Microbiology3.6%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)医学 4 区
类别学科分区
大类医学4 区
小类免疫学IMMUNOLOGY4 区

Top 期刊:否综述期刊:否

《新锐期刊分区表》( 2026年3月发布)医学 3 区
类别学科分区
大类医学3 区
小类免疫学IMMUNOLOGY3 区

Top 期刊:否综述期刊:未标注

期刊分区表( 2023年12月旧的升级版)未收录

该期刊未被此版本分区表收录。

期刊官网公布的 JCR / CiteScore 分区

出版商自述数据,JCR 以 Clarivate、CiteScore 以 Scopus 公布为准;与中科院分区是不同体系。出版商官网

数据库收录

ESCIScopusDOAJLetPub

国际期刊预警名单:各版本均未列入LetPub

期刊官网自述收录

Web of SciencePMCPubMedEmbaseCAS出版商官网

期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

影响因子(出版商公布)
3.3出版商官网 ·
影响因子(出版商公布) 2025
3.3出版商官网 ·
五年影响因子(出版商公布) 2025
4.1出版商官网 ·
CiteScore 2026-06
4.9LetPub ·
CiteScore(出版商公布)
4.9出版商官网 ·
SJR 2026-06
0.91LetPub ·
SNIP 2026-06
0.92LetPub ·
h-index
58OpenAlex ·
i10-index
354OpenAlex ·
两年平均被引
3.27OpenAlex ·
自引率
0%LetPub ·
Gold OA 文章占比
100%LetPub ·

发文规模

年文章数
109LetPub ·
年发文量(出版商公布)
1,985出版商官网 ·

逐年发文量 OpenAlex 统计 · 累计 880 篇 · 当年数据不完整

年份发文量其中 OA被引
2026868627
2025109109288
2024107107674
202381811,022
202278781,017
202152521,049

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

文章统计的审稿周期 PubMed 登记的稿件日期 · 至

44 天投稿到接收中位数 · P25–P75 36 天 – 60 天

接收到上线
中位数 5 天(111 篇)
投稿到上线
中位数 51 天
样本
111 篇有投稿与接收日期的文章(窗口内共 219 篇),最近一篇接收于

只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。

其他来源

平均审稿速度(社区反馈)
11 WeeksLetPub ·
投稿到首次决定
22.7 天出版商官网 ·
接收到发表
4.8 天出版商官网 ·
投稿到发表(期刊自报)
约 6 周DOAJ ·
评审方式
单盲同行评审DOAJ

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

完全开放获取DOAJ

所有文章开放获取,通常向作者收取文章处理费(APC)。

来源文章处理费费用减免许可证观测时间
DOAJCHF 1,800有CC BY
OpenAlexCHF 1,800——
LetPubCHF 1,800有—
出版商官网有,金额未公布——

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

征稿中的专刊2 个,按截稿日期
  1. Therapeutic Antibodies: New Trends in Discovery, Developability and Characterization截稿
  2. Immune Phenomena in Autoimmune Skin Disorders截稿
出版商官网
投稿准备要点7 项,摘自作者指南
摘要
≤ 250 词
参考文献格式
著者-出版年制
稿件模板
提供 LaTeX 与 Word 模板
首次投稿格式
允许不按期刊格式排版(free format)
推荐审稿人
必须提供 3 位
图文摘要
可选
投稿信(Cover letter)
必须提供
出版商官网 · 模型提取,逐项与原文核对
接收的文章类型18 种
  1. book reviewAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  2. brief communicationAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  3. brief reportAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  4. case reportAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  5. commentaryAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  6. conference reportAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  7. editorialAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  8. hypothesisAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  9. letterAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  10. opinionAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  11. perspectiveAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  12. protocolAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  13. registered reportAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  14. reviewAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  15. systematic reviewAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  16. technical noteAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  17. tutorialAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
  18. viewpointAll Article Types Article Review Communication Editorial Abstract Book Review Brief Communication Brief Report Case Report Clinicopathological Challenge Comment…未说明篇幅
出版商官网
官网政策摘录作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、预印本
作者资格 Authorship

MDPI遵循国际医学期刊编辑委员会(ICMJE)的作者资格标准,要求作者对工作的构思或设计、数据获取、分析或解释作出实质性贡献,起草或批判性审阅稿件,最终批准发表版本,并同意对工作的所有方面负责。 模型中文摘要

MDPI follows the International Committee of Medical Journal Editors (ICMJE) guidelines which state that, in order to qualify for authorship of a manuscript, the following criteria should be observed: Make substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work; Draft the work or review it critically for important intel…

原文 ↗出版商官网 ·
利益冲突 Conflicts of Interest

根据国际医学期刊编辑委员会的建议,作者应避免与研究资助方签订妨碍其获取全部研究数据或独立分析、解释数据及撰写和发表稿件能力的协议,且所有作者必须披露所有可能不当影响或偏倚其工作的关系或利益。 模型中文摘要

According to The International Committee of Medical Journal Editors, “Authors should avoid entering into agreements with study sponsors, both for-profit and non-profit, that interfere with authors’ access to all of the study’s data or that interfere with their ability to analyze and interpret the data and to prepare and publish manuscripts independently when and where they choose.” All authors mus…

原文 ↗出版商官网 ·
数据可用性 Data availability statements

MDPI发表的所有文章均需提供数据可用性声明;在同行评审和编辑决策过程中,作者可能被要求共享稿件中分析的现有数据集或原始数据,并说明其是否会在发表后提供给其他研究人员。 模型中文摘要

Data availability statements are required for all articles published with MDPI. During the peer review and editorial decision process, authors can be asked to share existing datasets or raw data that have been analyzed in the manuscript, and whether they will be made available to other researchers following publication. Authors will also be asked for the details of any existing datasets that have …

原文 ↗出版商官网 ·
出版伦理 Publication Ethics Statement

Antibodies是出版伦理委员会(COPE)成员,完全遵守其行为准则和最佳实践指南,编辑严格执行同行评审和伦理政策,并严肃处理抄袭、数据造假、图像操纵及不当署名等出版伦理问题。 模型中文摘要

Antibodies is a member of the Committee on Publication Ethics (COPE). We fully adhere to its Code of Conduct and to its Best Practice Guidelines. The editors of this journal enforce a rigorous peer review process together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsific…

原文 ↗出版商官网 ·
许可与版权 Copyright / Open Access

Antibodies发表的文章为开放获取文章,依据知识共享署名许可协议(CC BY)的条款和条件发布,版权由作者保留。 模型中文摘要

Articles published in Antibodies will be Open-Access articles distributed under the terms and conditions of the Creative Commons Attribution License (CC BY). The copyright is retained by the author(s). MDPI will insert the following note at the end of the published text: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and…

原文 ↗出版商官网 ·
开放获取 Open access publication fees

如果作者将稿件转投另一家开放获取(OA)期刊且文章被接受发表,将被收取文章处理费(APC),各期刊的APC可在其期刊网站上查询。 模型中文摘要

If you transfer your manuscript to another open access (OA) journal, you will be charged an Article Processing Charge (APC) if your article is accepted for publication. The APC for each journal can be found on the individual journal’s website. For more information about APCs, please see here.

原文 ↗出版商官网 ·
同行评审 Editorial Process and Peer Review

所有投稿均由领域内专家进行彻底的同行评审,并经过结构化的编辑流程,包括由编辑部执行的技术与伦理预审以及由学术编辑执行的编辑预审。 模型中文摘要

All submissions are thoroughly peer-reviewed by experts within the field and undergo a structured editorial workflow designed to ensure quality, transparency, and scientific integrity. The full editorial procedure is available on the Editorial Process page and is also provided below. Pre-check Pre-check consists of a technical pre-check performed by the Editorial Office and an editorial pre-check …

原文 ↗出版商官网 ·
预印本 Preprints and Conference Papers

Antibodies接受此前已作为预印本发布的投稿,前提是这些预印本未经同行评审;MDPI运营预印本服务器Preprints,发布预印本不影响同行评审过程。 模型中文摘要

Antibodies accepts submissions that have previously been made available as preprints provided that they have not undergone peer review. A preprint is a draft version of a paper made available online before submission to a journal. MDPI operates Preprints, a preprint server to which submitted papers can be uploaded directly after completing journal submission. Note that Preprints operates independe…

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
MDPI AG
出版国家或地区
Switzerland
出版语言
English
ISSN
2073-4468
官网最新一期
Volume 15(2026 年)
官方链接

常见问题

关于 Antibodies 的常见问题

Antibodies 是中科院几区期刊?

2025 年升级版分区表中,Antibodies 为医学 4区,小类 免疫学 4 区。2026 年新锐版分区表中为医学 3区。不同版本与大小类分区不能混用。

Antibodies 的影响因子是多少?

期刊官网公布的影响因子为 3.3,属期刊自述数据,LetPub 暂无该刊的影响因子记录,CiteScore 为 4.9,h-index 为 58。

Antibodies 的审稿周期多长?

按 2024年10月至2026年10月(近 24 个月)111 篇已发表文章登记的日期,投稿到接收的中位数为 44 天(四分位 36–60 天);投稿社区反馈的平均审稿速度为约 11 周。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

Antibodies 的投稿格式要求是什么?

据期刊作者指南:摘要:≤ 250 词;参考文献格式:著者-出版年制;稿件模板:提供 LaTeX 与 Word 模板;首次投稿格式:允许不按期刊格式排版(free format);推荐审稿人:必须提供 3 位;图文摘要:可选;投稿信:必须提供。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。

Antibodies 被哪些数据库收录?

据 LetPub 与 DOAJ 记录,Antibodies 被 ESCI、Scopus、DOAJ 收录。期刊官网自述还被 Web of Science、PMC、PubMed、Embase、CAS 收录,该清单未与各数据库逐一核对。

Antibodies 是开放获取期刊吗?版面费多少?

Antibodies 为完全开放获取。收取 APC,金额未公布。

来源与更新

本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。